Tuesday, September 25, 2018
 
 
Company News: Page (1) of 1 - 07/24/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Janssen Presents Switch Data for New HIV-1 Treatment SYMTUZA™ (D/C/F/TAF) and Second Study Supporting its Use in a Rapid Initiation Scenario
Phase 3 EMERALD and DIAMOND studies at AIDS 2018 reinforce the safety and efficacy of SYMTUZA™ (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg), the fi...
(July 24, 2018)
This article is no longer available,but here are some related topics.


Page: 1


Related Keywords:USA,Medicine,Disease,Sexual,healthcare,Pregnancy,Surgery,Medication,Vitamins/Nutrition,Womens Health,Pregnancy,Physician,Health Technologist,Science,Medical,Biology,Genetics,Science,Adults,Other,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
 
 
 
 
 





Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines